血清P53抗体与原发性肝癌临床特征的关系  

Relationship between serum anti-P53 antibody and clinical characteristics of primary hepatic carcinoma

作　　者：官泳松[1] 刘源[1] 贺庆[1] 

机构地区：[1]四川大学华西医院放射科,四川省成都市610041

出　　处：《世界华人消化杂志》2007年第3期246-253,共8页World Chinese Journal of Digestology

摘　　要：目的:分析原发性肝癌(primary hepatic carcinoma,PHC)患者血清P53抗体与临床特征的关系.方法:用ELISA法定量分析68例肝癌患者首诊时血清P53抗体,并用单因素和多因素统计方法分析与性别、年龄、饮酒史、HbsAg、KPS评分、病理诊断、肿瘤分化程度、肝硬化、肿瘤生长方式、肿瘤分期、血管侵犯、有无肝外转移、Child分级、血清白蛋白、AFP、血清铁蛋白等的相关性.结果:68例PHC血清P53抗体阳性率29.4%(20/68).单因素分析显示,血清P53抗体阳性与肿瘤分化程度低(P=0.020)、肝外转移(P=0.002)、肿瘤分期晚(P=0.027)、血管侵犯有关(P=0.010).多因素分析显示只有肝外转移与P53抗体阳性有关(OR=4.185,P=0.022).结论:血清P53抗体阳性与PHC的不良生物学特征有关.AIM： To analyze the level of serum anti-P53 antibody in primary hepatic carcinoma （PHC） as well as its correlation with clinical characteristics. METHODS： The enzyme-linked immunosorbent assay （ELISA） was used to detect the serum level of anti-P53 antibody in 68 patients with PHC. Univariate analysis and multivariate Logistic regression analysis were performed to investigate the correlation between the serum level of P53 antibody and clinical data, including the age, sex of patients, alcohol intake, HBsAg, KPS scores, pathological findings, differentiation degree, liver cirrhosis, pattern of tumor growth, tumor stages, vascular invasion, remote metastasis, Child class, the level of serum albumin, alphafetoprotein （AFP） and ferritin. RESULTS： A total of 20 patients （29.4%） were detected positive for serum anti-P53 antibody. Univariate analysis revealed that the positive status of serum P53 antibody was associated with the degree of differentiation （P = 0.020）,remote metastasis （P = 0.002）, tumor stages （P = 0.027） and vascular invasion （P =0.010）. Multivariate analysis showed that only remote metastasis was independently associated with the positive status of serum anti-P53 antibody （OR = 4.185, P = 0.022）. CONCLUSION： The positive status of serum P53 antibody may be associated with the malignant biological features and poor prognosis of PHC.

关 键 词：血清P53抗体 原发性肝癌 临床特征 酶链免疫吸附法 

分 类 号：R735.7[医药卫生—肿瘤]